Quantcast

Latest Friedreich's ataxia Stories

2010-01-15 17:38:35

Biomarkers, new treatments possible for Friedreich's ataxia Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI). The findings, described today in PLoS Genetics, shed light on the molecular abnormalities that lead to the disease, as...

2009-12-15 08:00:00

WALTHAM, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA). This grant will support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials. Support from the MDA not only provides important funding for...

2009-11-05 06:00:00

WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008. Total revenue for the second quarter of fiscal year 2010 was comprised of Protein A product revenue of $2,742,000 and royalty and research revenue of $2,679,000,...

2009-09-26 08:58:00

Discovery takes researchers 1 step closer to human clinical trials and could improve understanding of other diseases Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials,...

2009-09-25 11:15:00

WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. The study entitled "Chemical Probes...

2009-08-06 06:00:00

WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. Total revenue for the quarter was $5,061,000 compared to total revenue of $13,660,000 for the first quarter of fiscal year 2009. The prior year results were favorably impacted by a one-time payment of $6,330,000 by Bristol-Myers Squibb Company for royalties on the U.S. sales of Orencia(R) prior to the April 2008 patent...

2009-07-09 11:48:34

Researchers in human genetics have long known that expansions of GAA repeats "“ resulting in this nucleotide triplet repeating hundreds or thousands of times "“ cause the most common hereditary neurological disorder known as Friedreich's ataxia. There is no cure for this condition, which damages the nervous system and can result in heart disease.The disease's origins have been proven through analysis of genetic records of affected individuals and their families. But scientists...

2009-04-01 07:00:00

Will Apply VC Business Practices to Funding Research TUCSON, Ariz., April 1 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) today announced the launch of a new initiative, MDA Venture Philanthropy (MVP), which will be a wholly owned subsidiary of MDA. A 501(c)(3) nonprofit organization, MVP will break with traditional philanthropy models for funding research by applying the tools of venture capital firms to fast track the development of new therapies and cures for...

2008-12-22 15:22:00

ST. PETERSBURG, Fla., Dec. 22 /PRNewswire/ -- On December 17th, the new Bonefish Grill restaurant located at 5062 4th Street North in St. Petersburg, opened its doors to friends and supporters of Friedreich's Ataxia Research Alliance for Heineken with a Heart, a social event sponsored by Bonefish Grill, SafeCall and Heineken USA to benefit local charities. (Logo: http://www.newscom.com/cgi-bin/prnh/20080212/CLTU083LOGO ) Guests took part in complimentary Bonefish Grill delights...

2008-11-06 09:00:45

WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the second quarter of fiscal year 2009, ended September 30, 2008. Total revenue for the quarter was $5,090,000 compared to total revenue of $5,352,000 for the second quarter of fiscal year 2008 ended September 30, 2007. Total revenue was comprised of product revenue and royalty and research revenue. Product revenue, comprised of Protein A revenue, for the second quarter of fiscal year 2009...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related